Amgen, Horizon Blast FTC's 'Speculation On Speculation'
By Bryan Koenig · June 12, 2023, 8:19 PM EDT
Amgen and Horizon Therapeutics insisted that the Federal Trade Commission's challenge to their merger is undone by real-world market dynamics that make it impractical to bundle products that, as the agency...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login